Ph.D., Health Education, Texas Woman's University, 1977
M.A., Health Education, Texas A & I University, Kingsville, 1972
B.A., Health Education, Texas Tech University, 1969
Structured Clinical Interview for Axis I DSM-IV Disorder (SCID), 1994
Mini International Neuropsychiatric Interview (MINI), 1999
Hamilton Rating Scale for Depression (HAM-D), 1999
Hamilton Anxiety Scale (HAM-A), 1999
Montgomery Asberg Depression Rating Scale (MADRS) 2000
NIH's Human Participants Protection Education for Research Teams Training, February 2001
Association of Clinical Research Professionals, Good Clinical Practices for Clinical Investigators
3-day Training, 2002
HLTH 742: Professional Writing
- Smoking Cessation
- Smokeless Tobacco
Selected Publications (within last 10 years)
Cooke CE, Glover ED, Xing S, Lee HY. (2011) Failure to obtain Varenicline in members with pharmacy benefits. The American Journal of Pharmacy Benefits, May/June 3(3): e36-e40.
Hatsukami DK, Jorenby DE, Gonzales D, Rigotti N, Glover ED, Oncken C, Tashkin D, Reus V, Akhavain R, Fahim REF, Kessler PD, Niknian M, Kalnik MW, Rennard SI. (2011) Immunogenicity and smoking cessation outcomes for a novel nicotine immunotherapeutic: anti-nicotine elicited antibodies enhance quitting and support long-term abstinence. Clinical Pharmacology Therapeutics. 2011. DOI 1038/clpt.2010.317.
McDermott RJ, Glover ED. (2010) Formation and early history of The American Academy of Health Behavior. American Journal of Health Behavior, 34(5):563-572.
Glover ED, Rath J, Sharma E, Glover PN, Laflin MT, T°nnesen P, Repsher L, Quiring J. (2010) A multi-center, phase-3 trial of lobeline sulfate for smoking cessation. American Journal of Health Behavior, 34(1):101-109.
Ebbert JO, Glover ED, Shinozaki E, Schroeder DR, Dale LC. (2008) Predictors of smokeless tobacco abstinence. American Journal of Health Behavior, 32(6):735-740.
Nides M, Glover ED, Reus V, Christen AG, Make BJ. (2008) Varenicline versus bupropion or placebo for smoking cessation. American Journal of Health Behavior, 32(6):664-675.
Dale LC, Ebbert JO, Glover ED, Croghan IT, Schroeder DR, Severson HH, Hurt RD. (2007) Bupropion SR for the treatment of smokeless tobacco use. Drug and Alcohol Dependence, 90(1):56-63.
Stevens AB, McDaniel KS, Glover ED, Wallace KS. (2007) Are instructions for over-the-counter nicotine replacement therapy readable? American Journal of Health Behavior, 31(Suppl 1):S79-S84.
Glover ED, Rath JM. (2007)Varenicline: progress in the treatment of smoking cessation treatment. Expert Opinion Pharmacotherapy, 8(11):1757-1767. (Invited)
Glover ED, Laflin MT, Schuh KJ, Schuh L, Nides M, Christen AG, Glover PN, Strnad JV. (2007) A randomized, controlled trial to assess the efficacy and safety of a transdermal delivery system of nicotine/mecamylamine in cigarette smokers. Addiction, 102:795-802.
Glover ED, Glover PN, Laflin M, Nochur SV, Strnad JV. (2007) Sensitivity and specificity of a reagent-impregnated test strip in identifying smokeless tobacco users. Nicotine & Tobacco Research, 9(4):499-503.
Rennard SI, Glover ED, Leischow S, Daughton D, Glover PN, Muramoto M, Franzon F, Danielsson T, Landfeldt B, Westin A. (2006) Efficacy of nicotine inhaler in smoking reduction: a double-blind, randomized trial. Nicotine & Tobacco Research, 8(4):555-564.
Gonzales D, Rennard SI, Nides M, Onchen C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves (2006) KR for the Varenicline Phase 3 Study Group. Varenicline, an a4▀2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation: a randomized control trial. Journal of the American Medical Association, 2006;296(1):47-55 (July 5). (I served as a PI for one of the centers in the US and was listed in the Varenicline Phase 3 Study Group.)
Glover ED. (2006) Successfully treating nicotine dependence: AAHPERD scholar address. American Journal of Health Education, 37(1):6-14.
DeprÚs JP, Golay A, Sj÷str÷m L, for the Rimonabant in Obesity-lipids Study Group. (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New England Journal of Medicine, 353(20):2121-2134 November 17. (I served as a PI for one of the centers in the US and was listed in the Rimonabant In Obesity-lipids Study Group.)
Niaura R, Sayette M, Shiffman S, Glover ED, Nides M, Shelanski M, Shadel W, Koslo R, Robbins B, Sorrentino J. (2005) Comparative efficacy of rapid-release nicotine gum vs nicotine polacrilex gum in relieving smoking cue-provoked craving. Addiction, 100(11):1720-1730.
Laflin M, Glover ED, McDermott RJ. (2005) Publication ethics: an examination of authorship practices. American Journal of Health Behavior, 29(6):579-587.
Glover ED, Nilsson F, Westin A, Glover PN, Laflin M. (2005) Developmental history of the Glover-Nilsson Smoking Behavioral Questionnaire (GN-SBQ). American Journal of Health Behavior, 29(5):443-455.
Glover ED. (2004) A new health education paradigm: uncommon thoughts about common matters. AAHE scholar address. American Journal of Health Education, 35(5):260-271.
Glover ED, Glover PN, Payne TJ. (2003) Treating nicotine dependence. American Journal of Medical Sciences, 326(4):183-186.
Sullivan P, Sinz E, Hobbs G, Glover ED, Cain J, Kofke A. (2003) Remifentanil Vs. Methohexital for Electroconvulsive Therapy. Journal of Electroconvulsive Therapy, 19(1):60.
Glover ED, Glover PN, Franzon M, Sullivan CR, Cerullo CL, Howell RM, Keyes GG, Nilsson F, Hobbs GR. (2002) A comparison of a nicotine sublingual tablet & placebo for smoking cessation. Nicotine & Tobacco Research, 4:441-450.
Glover ED, Glover PN, Sullivan CR, Cerullo C, Hobbs GR. (02) A comparison of sustained-release bupropion & placebo for smokeless tobacco cessation. American Journal of Health Behavior, 26;(5):386-393.
Sullivan P, Sinz E, Hobbs G, Glover E, Cain J, Kofke A. (2002) Remifentanil Vs. Methohexital for Electroconvulsive Therapy. International Journal of Psychiatry in Clinical Practice, 6(4):254-255.
Glover ED, Tucker VL, Winter PD. (2001) Efficacy and tolerability of bupropion SR for smoking cessation. World Journal of Biological Psychiatry, 2(1)270S.
Johnston JA, Fiedler-Kelly J, Glover ED, Sachs DPL, Grasela T, DeVeaugh-Geiss J. (2001) Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation. Nicotine & Tobacco Research, 3(2):131-140.
Dale LC, Glover ED, Sachs DPL, Schroeder DR, Offord KP, Croghan IT, Hurt RD. (2001) Bupropion for smoking cessation-predictors of successful outcome. Chest, 119:1357-1364.
Glover ED, Glover PN. (2001) Pharmacological treatments for the nicotine dependent smoker. American Journal of Health Behavior, 25(3):179-182.
Glover ED, Glover PN. (2001) Treating nicotine dependence. The West Virginia Medical Journal, 97:39-42.
Recent Grants (within last 7 years)
Pfizer Inc, A Phase 4 Randomized Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Re-treatment with Varenicline in Subjects Who are Currently Smoking, and Have Previously Taken Varenicline, Principal Investigator
Nabi Pharmaceuticals, A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Follow-up Safety Study to Assess Long-term Immunogenicity and Safety of 3'-aminomethlnicotine-P. aeruginosa r-Exoprotein Conjugate Vaccine (NicVax) as an Aid to Smoking Cessation, Principal Investigator
Nabi Pharmaceuticals, Health-Related Quality of Life and Health-Care Resource Utilization Assessment in Nabi 4514 and Nabi 4515 Phase 3 Studies, Principal Investigator
University of Maryland-College Park and the University of Maryland-Baltimore Research Program, Interaction of the Human Microbiome and Tobacco in Women's Reproductive Health, Co-Principal Investigator
Nabi Pharmaceuticals, A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy, Immunogenicity and Safety of 3'-aminomethylnicotine-/P. aeruginosa/ r-Exoprotein A Conjugate Vaccine (NicVAX« ) as an Aid to Smoking Cessation, Principal Investigator
Nabi Pharmaceuticals, A Study to Assess Efficacy of NicVax in Smokers Who Want to Quit Smoking, Principal Investigator
Pfizer Inc, Phase I, Randomized Double-Blind, Placebo-Controlled Study to Evaluate the Multiple-dose Pharmacokinetics, Safety & Tolerability of Varenicline in Healthy Adolescent Smokers, Principal Investigator
Pinney Associates and Concentrics, Study to Assess the Efficacy of 4mg Nicotine Lozenge vs. Varenicline in Relief of Provoked Craving, Principal Investigator
National Institute of Drug Abuse & the Department of Veterans Affairs, Phase 2, Double-Blind, Placebo-Controlled Trial of Selegiline as an Aid to Smoking Cessation, Principal Investigator
Sanofi-Aventis, An International, Seven-Week, Double-Blind, Placebo-Controlled Two Parallel Group Study to Assess the Efficacy of SSR591813L 40 mg BID as an Aid to Smoking Cessation in Cigarette Smokers, Principal Investigator
Pharmacia & Upjohn Company LLC (Pfizer), A Multi-center, Randomized, Parallel Group, Comparative Trial to Evaluate the Efficacy of Nicotine Hydrogen Tartrate Gum (4m) and a Coated Nicotine Polacrilex Gum (4mg) Versus Uncoated Nicotine Polacrilex Gum (4mg) on the Speed to Subjectively Meaningful Relief of Acute Craving in Adult Smokers, Principal Investigator
NABI Pharmaceuticals, A Phase 2, Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Study to Assess Safety and Immunogenicity of Two doses of 3'-aminomethylnictone-P. aeruginosa r-Exoprotein A Conjugate Vaccine (NicVax) in Two Different Dosing Schedules in Smokers Who Want to Quit, Principal Investigator
National Institute of Drug Abuse, Appalachian TriState Node of Clinical Trials Network Research Project. 5-Year Study (2005-2009), Co-Principal Investigator
Sanofi-Aventis, An Eight-Week, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety and Tolerability of One Fixed 100 mg Dose of Saredutant in Patients with Major Depressive Disorder, Principal Investigator
Bristol Myers Squibb, A Multicenter, Long-Term, Open-Label Study to Assess the Safety and Tolerability of Aripirazole as Adjunctive Therapy in the Treatment of Outpatients with Major Depressive Disorder, Principal Investigator
GlaxoSmithKline, Cortical Myelin Preservation in Schizophrenic Patients, Co-Investigator
Sanofi-Synthelabo, A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study to Assess Efficacy & Safety of Rimonabant 20 mg versus Placebo on Weight Loss & Frequency of Binge Episodes in Obese Patients with Food Craving, Principal Investigator
National Institutes of Health (NIH-1R01 CA90884-01A1). Efficacy of Bupropion for Treating Spit Tobacco Users, Co-Investigator
Awarded, Campbell University, Evaluation of 24 Hours Motor Activity of Bupropion XL vs Placebo in Patients with Major Depressive Disorder, Principal Investigator
Sanofi-Synthelabo Comparison of the Efficacy & Safety of 3 Oral Doses of SSR591813, 20 mg, 40 mg, 80 mg Twice Daily, Versus Placebo as an Aid to Smoking Cessation. A US, Multicenter, Randomized, Double-blind, 4-arm, Fixed Dose, 7-week Treatment, Phase II Trial, Principal Investigator
AstraZeneca, A Multicenter, Randomized, Parallel-group, Double-blind, Phase III Comparison of the Efficacy & Safety of Quetiapine Fumerate (oral tablets 400 mg to 800 mg daily in divided doses) to Placebo When Used as Adjunct to Mood Stabilizers (Lithium or Divalproex) in the Maintenance Treatment of Bipolar I Disorder in Adult Patients, Co-Investigator
Sanofi-Synthelabo, A Dose-Ranging Placebo-Controlled Study of SL64.0155-10 at the Doses of 0.5 mg, 2 mg, and 8 mg for 12 Weeks in Patients with Mild-to-Moderate Alzheimer's Disease, Co-Investigator
Sanofi-Synthelabo, A Double-Blind, Multicenter Study Evaluating the Efficacy and Safety of One Fixed Dose of SR58611A (700 mg/day) Versus Placebo and Paroxetine (20 mg/day) in Patients with a Recurrent Major Depressive Episode, Co-Investigator
National Institutes of Health (NIH-1R01 CA90884-01A1). Efficacy of Bupropion for Treating Spit Tobacco Users, Co-Investigator
Sanofi-Synthelabo, Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 4 mg/day or 20 mg/day Versus Placebo as an Aid to Prevention of Relapse to Smoking - a Multiple Country (Worldwide), Randomized, Double-Blind, 3-arm, Placebo-Controlled, Parallel-Group, Fixed Dose, 2-Year, Multicenter, Phase III Trial: 1-Year Active Treatment, 1-year-Followup, Principal Investigator
Pfizer, Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study with Follow-Up Evaluating the Safety & Efficacy of Varenicline Tartrate (CP-526,555) in Comparison to Zyban for Smoking Cessation, Principal Investigator
- Professor & Chair, Department of Behavioral & Community Health, & Founding Director of the Center for Health Behavior Research, University of Maryland School of Public Health, College Park, MD.
- An internationally recognized authority on the topics of smoking cessation & smokeless tobacco with more than 200 publications to his credit.
- Work has appeared in such noted publications as the N Engl J Med, JAMA, Am J Public Health, Archives of Otolaryngology, Addictive Behaviors, Nicotine and Tobacco Research, & others.
- One of the 28 scientists selected to contribute to the 1994 Surgeon General Report on Tobacco & Youth.
- Delivered approximately 550 medical grand rounds/workshops on treating nicotine dependence to medical health professionals throughout the world.
- Delivered approximately 335 national & international professional presentations to various medical & health professional organizations around the world.
- Serves in various capacities for 20 key health journals and/or publications.
- Editor of the American Journal of Health Behavior & founder of the American Academy of Health Behavior.
- Named the 2003 Distinguished Scholar for the American Association of Health Education (AAHE) and the 2005 Alliance Scholar for AAHPERD.
- Selected by the University of Maryland as a "Rainmaker" a Research Leader for 2007 and 2008.